Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Study Phase: Phase 3
Recruitment Status: Recruiting
Start Date: November 06, 2023
End Date: October 31, 2033
Inclusion Criteria:
- Active UC with an AMS of 5 to 9 points and endoscopic subscore of 2 to 3.
- Demonstrate an inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy.
Exclusion Criteria:
- Partcipants with previous exposure to JAK inhibitors (e.g., tofacitinib, baricitinib, filgotinib, upadacitinib).
- Females who are pregnant, breastfeeding, or considering becoming pregnant during the study and for approximately 30 days after the last dose of study drug.
-
Conditions:
- Colitis
- Colitis, Ulcerative
- Ulcer